liquid biopsy for breast cancer

Release time ：Dec-19,2024

Liquid biopsy is a novel technique for detecting breast cancer that involves analyzing tumor DNA and other biomarkers in the blood to diagnose and monitor the disease's progression. This minimally invasive approach is more convenient than traditional tissue biopsies and allows for real-time tracking of cancer dynamics.

The utility of liquid biopsy in breast cancer is evident in several key areas. Firstly, it aids in the early detection of breast cancer by identifying circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the bloodstream, thus uncovering potential tumor signals. Secondly, it can monitor treatment responses by regularly assessing tumor marker levels in the blood, enabling physicians to evaluate the efficacy of treatments and adjust therapeutic strategies promptly. Additionally, liquid biopsy can predict the risk of breast cancer recurrence by detecting specific genetic mutations in the blood, assisting doctors in devising personalized follow-up plans.

For breast cancer patients, recognizing the significance of liquid biopsy and actively engaging in testing with their healthcare providers is crucial. Patients should also adhere to their physicians' recommendations for the proper scheduling of treatments and follow-up appointments to enhance therapeutic outcomes and overall quality of life.